Moderna, Inc.: Moderna Announces its COVID-19 Vaccine Phase

Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this age

Related Keywords

Australia , Cambridge , Cambridgeshire , United Kingdom , Canada , Lavina Talukdar , Colleen Hussey , Exchange Commission , Corporate Communications , European Medicines Agency , Moderna Inc , Drug Administration , Nasdaq , Chief Executive Officer , Vaccine Adverse Event Reporting System , Private Securities Litigation Reform Act , Annual Report , Vice President , Moderna , Nnounces , Covid , Vaccine , Hase , Study , Children , Months , Under , Tears , Uccessfully , Primary , Ndpoint ,